Immunohistochemical Evaluation of Androgen Receptor, HER-2/neu, and p53 in Benign Pleomorphic Adenomas

被引:0
|
作者
DeRoche, Tom C. [1 ]
Hoschar, Aaron P. [1 ]
Hunt, Jennifer L. [1 ]
机构
[1] Cleveland Clin, Dept Anat Pathol, Cleveland, OH 44106 USA
关键词
D O I
暂无
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Context.-Immunohistochemical stains for androgen receptor (AR), HER-2/neu, and p53 are used as diagnostic markers associated with malignancy in several histologic types of salivary gland tumors. These markers may be useful in differentiating pleomorphic adenoma with cytologic atypia from intracapsular carcinoma ex pleomorphic adenoma (CXPA), as these tumors are often difficult to distinguish on the basis of morphology alone. Objective.-To determine whether AR, HER-2/neu, and p53 expression can be seen in entirely benign pleomorphic adenomas. Design.-Androgen receptor, HER-2/neu, and p53 immunoreactivity was assessed in 41 histologically and clinically benign pleomorphic adenomas. Results.-A total of 3 of 41 pleomorphic adenomas exhibited multifocal areas with moderate staining for HER-2/neu and AR. The positive staining was mainly confined to the epithelial component, where the ductal epithelium showed no cytologic atypia. Immunoreactivity for p53 was observed in the epithelial component of 5 of 41 cases, none of which stained for HER-2/neu and AR. Mean mitotic rate and Ki-67 index were 1 per 10 high-powered fields and 2.7% in HER-2/neu- and AR-positive cases and 1 per 10 high-powered fields and 2.2% in p53-positive cases. Conclusions.-HER-2/neu, AR, and p53 are expressed in a subset of histologically and clinically benign pleomorphic adenomas. These markers cannot be used to reliably predict early carcinomatous transformation in pleomorphic adenoma.
引用
收藏
页码:1907 / 1911
页数:5
相关论文
共 50 条
  • [31] P53 overexpression predicts endometrial carcinoma recurrence better than HER-2/neu overexpression
    Coronado, PJ
    Vidart, JA
    Lopez-asenjo, JA
    Fasero, M
    Furio-bacete, V
    Magrina, J
    Escudero, M
    EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2001, 98 (01): : 103 - 108
  • [32] HER-2/neu overexpression in breast cancer: An immunohistochemical study including correlations with clinicopathologic parameters, p53 oncoprotein and cathepsin-D
    Korkolis, D
    Ardavanis, A
    Yotis, J
    Kyroudi, A
    Gorgoulis, V
    Kittas, C
    ANTICANCER RESEARCH, 2001, 21 (3C) : 2207 - 2212
  • [33] Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status
    Brodowicz, T
    Kandioler, D
    Tomek, S
    Ludwig, C
    Rudas, M
    Kunstfeld, R
    Koestler, W
    Hejna, M
    Budinsky, A
    Krainer, M
    Wiltschke, C
    Zielinski, CC
    BRITISH JOURNAL OF CANCER, 2001, 85 (11) : 1764 - 1770
  • [34] Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status
    T Brodowicz
    D Kandioler
    S Tomek
    C Ludwig
    M Rudas
    R Kunstfeld
    W Koestler
    M Hejna
    A Budinsky
    C Wiltschke
    C C Zielinski
    British Journal of Cancer, 2001, 85 : 1764 - 1770
  • [35] Immunohistochemical determination of HER-2/neu in malignant melanoma
    Potti, A
    Hille, R
    Koch, M
    ANTICANCER RESEARCH, 2003, 23 (5A) : 4067 - 4069
  • [36] EXPRESSION OF NEU/HER-2 ONCOPROTEIN (P185(NEU)) IN PROSTATE TUMORS - AN IMMUNOHISTOCHEMICAL STUDY
    GIRI, DK
    WADHWA, SN
    UPADHAYA, SN
    TALWAR, GP
    PROSTATE, 1993, 23 (04): : 329 - 336
  • [37] Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancer
    Han, H
    Landreneau, RJ
    Santucci, TS
    Tung, MY
    Macherey, RS
    Shackney, SE
    Sturgis, CD
    Raab, SS
    Silverman, JF
    HUMAN PATHOLOGY, 2002, 33 (01) : 105 - 110
  • [38] Salivary duct carcinoma: Immunohistochemical analysis of androgen receptor, prostatic markers and HER-2/neu oncoprotein in 40 cases.
    Kay, PA
    Roche, PC
    Olsen, KD
    Lewis, JE
    LABORATORY INVESTIGATION, 2001, 81 (01) : 150A - 150A
  • [39] The efficacy of trastuzumab in Her-2/neu-overexpressing metastatic breast cancer is independent of p53 status
    Köstler, WJ
    Brodowicz, T
    Hudelist, G
    Rudas, M
    Horvat, R
    Steger, GG
    Singer, CF
    Attems, J
    Rabitsch, W
    Fakhrai, N
    Elandt, K
    Wiltschke, C
    Hejna, M
    Zielinski, CC
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2005, 131 (07) : 420 - 428
  • [40] Histopathology study and antigen p53, Ki67, Her-2/neu manifestation in colorectal cancer
    Khien Van Vu
    Cong Hong Vo
    Dung Tuan Trinh
    Dung Tuang Trinh
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 318 - 318